Quick Answer
Alzamend Neuro, Inc. reported Diluted EPS of $11.32 per share (loss) for fiscal year 2025.
Alzamend Neuro, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$11.32 | +91.4% |
| 2024 | -$132.33 | -478.1% |
| 2023 | -$22.89 | -16250.0% |
| 2022 | -$0.14 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| October 31, 2025 | -$0.30 | +91.7% | +76.6% |
| July 31, 2025 | -$1.28 | +88.8% | -573.7% |
| January 31, 2025 | -$0.19 | +95.0% | +94.7% |
| October 31, 2024 | -$3.61 | +18.5% | +68.4% |
| July 31, 2024 | -$11.42 | -112.3% | -202.9% |
| January 31, 2024 | -$3.77 | -354.2% | +14.9% |
| October 31, 2023 | -$4.43 | -822.9% | +17.7% |
| July 31, 2023 | -$5.38 | -17833.3% | -548.2% |
- Alzamend Neuro, Inc. showed an increase of +91.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, Alzamend Neuro, Inc.’s diluted eps has declined by 7985.7% (from $0.14 per share (loss) to $11.32 per share (loss)).
- The most recent figure is from Alzamend Neuro, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on July 22, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: